BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, May 13, 2026
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

Other news to note for Aug. 5, 2020

Aug. 5, 2020
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aura Smart Air, Axim, Back 2 Basics Direct, BehaVR, Biotechnologies, Brainworks, Entrepix Medical, Eurofins, Fujirebio Diagnostics, H.U. Group Holdings, Iremedy, Medtronic, MeMD, Merchavia Holdings and Investments, Mevion Medical Systems, Orbbö Surgical, Sumitomo Dainippon Pharma, Sunovion Pharmaceuticals, Targetcancer Foundation, Tecan Group, Thermo Fisher Scientific, Trendlines Group, Withmydoc, W.L. Gore, Viacyte, Wishbone Medical, Zenzium.
Read More
Coronavirus vaccine illustration

COVID-19 vaccine race growing ‘titer’ as Novavax unveils phase I data

Aug. 5, 2020
By Randy Osborne
With strong results in hand from the phase I stage of its phase I/II study testing a would-be COVID-19 subunit vaccine, Novavax Inc.’s president of R&D, Gregory Glenn, said “it’s possible we could go down in the dose” as work proceeds and get similar efficacy.
Read More

Regulatory actions for Aug. 5, 2020

Aug. 5, 2020
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Axsome, Diurnal, Pharmacyte, Revive.
Read More

Other news to note for Aug. 5, 2020

Aug. 5, 2020
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Adicet, Aerpio, Alvotech, Celularity, Cohbar, Evotec, Genfit, IMV, Recursion, Regeneron, Scholar Rock, Secarna, Specifica, SRI, Teva, Therapeutics Solutions, Torii, VBI, Verrica, Viacyte, Vyripharm.
Read More

In the clinic for Aug. 5, 2020

Aug. 5, 2020
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Algernon, Axcella, Biontech, Clovis, Cytodyn, Elios, Emmaus, Fosun, Hepion, KBP, Modag, Novavax, Palatin, Pfizer.
Read More
Antibodies attacking SARS-CoV-2 virus

Siemens Healthineers nabs first FDA nod for semi-quantitative SARS-CoV-2 antibody test

Aug. 4, 2020
By Stacy Lawrence
The U.S. FDA gave an emergency use authorization (EUA) to the first semi-quantitative antibody test from Siemens Healthineers AG for the SARS-CoV-2 virus. This test, known as the SARS-CoV-2 IgG (COV2G) antibody test, could potentially be used repeatedly over time to assess relative levels to gauge potential immunity.
Read More
Coronavirus and stock charts

Despite fall in net sales, Zimmer Biomet beats consensus in Q2

Aug. 4, 2020
By Liz Hollis
Orthopedic companies felt pressure from COVID-19 in their most recent quarters. For example, Zimmer Biomet Holdings Inc. reported second-quarter net sales of $1.226 billion, a decrease of 38.3% from the prior-year period. Still, those revenues did come ahead of expectations, as Wells Fargo analyst Larry Biegelsen noted – $432 million ahead of his group's estimate and $305 million ahead of consensus.
Read More

Regulatory actions for Aug. 4, 2020

Aug. 4, 2020
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abiomed, Biotricity, Siemens Healthineers.
Read More

Other news to note for Aug. 4, 2020

Aug. 4, 2020
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: 10x Genomics, Abbott, Adagio Medical, Adaptive Biotechnologies, Aesthetic Laser Partners, Aesthetic Mobile Laser Services, Ams, Avid Product Development, Balt, Berkeley Data Ventures, Bio-Rad, Cerus Endovascular, Crank Software, Daxor, De Novo Software, Electromedical, Exagen, Fluidigm, Genuity Science, Htg Molecular Diagnostics, Imricor Medical Systems, Intertek, Launchpad Medical, Lubrizol, Matrix Medical Network, Midge Medical, Nashville Biosciences, Penlon, Precipio, Revbio, Royal Philips, Sensus Healthcare, Solos Health Analytics, Think Surgical, United Orthopedic, Transenterix, Tüv Rheinland, Usgi Medical, Ventec Life Systems, Xleratehealth.
Read More

BioWorld MedTech’s Oncology Extra for Aug. 4, 2020

Aug. 4, 2020
By Mark McCarty
Keeping you up to date on recent developments in oncology, including: Cancer follow-up plummeted in Wuhan after onset of COVID-19 pandemic; T-cell receptor sequencing proves useful for tracking thyroid cancer; Silver nanowires take their place in brain cancer therapy.
Read More
Previous 1 2 … 399 400 401 402 403 404 405 406 407 … 552 553 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 13, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 12, 2026
  • Brain maze

    Alzheimer’s, beyond the brain

    BioWorld
    Researchers at Daping Hospital in China have reported that liver-targeted delivery of the APOE3-Christchurch (APOE3Ch) variant, a rare protective form of...
  • Hantavirus zoonotic spillover illustration

    First cruise ship hantavirus genome points to zoonotic spillover

    BioWorld
    The initial appraisal of the first complete genome sequence of a hantavirus isolated from a patient in Switzerland who was a passenger on the cruise ship MV...
  • Test tubes, dropper and capsules

    Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal

    BioWorld
    In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing